复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02196 复星医药

已收盘 05-07 16:08:25

13.980

+0.040

+0.29%

最高14.300	最低13.960	成交量369.55万
今开14.180	昨收13.940	日振幅2.44%
总市值372.29亿	流通市值75.91亿	总股本26.63亿
成交额5,192万	换手率0.68%	流通股本5.43亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":13.98,"timestamp":1746605305016,"preClose":13.94,"halted":0,"volume":3695500,"delay":0,"floatShares":543000000,"shares":2663000000,"eps":1.1139865353214071,"marketStatus":"已收盘","change":0.04,"latestTime":"05-07 16:08:25","open":14.18,"high":14.3,"low":13.96,"amount":51924067,"amplitude":0.02439,"askPrice":13.98,"askSize":2500,"bidPrice":13.96,"bidSize":76000,"shortable":3,"etf":0,"ttmEps":1.1778689352531384,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746667800000},"marketStatusCode":5,"adr":0,"listingDate":1351526400000,"exchange":"SEHK","adjPreClose":13.94,"dividendRate":0.024374,"openAndCloseTimeList":[[1746581400000,1746590400000],[1746594000000,1746604800000]],"volumeRatio":0.821067,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":23.81,"timestamp":1746601200000,"preClose":23.69,"halted":0,"volume":12618800,"delay":0,"premium":"-45.33"}},"requestUrl":"/m/hq/s/02196","defaultTab":"news","newsList":[{"id":"2533505263","title":"复星医药累计回购731.06万股A股及236.5万股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2533505263","media":"智通财经网","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533505263?lang=zh_cn&edition=full","pubTime":"2025-05-06 17:09","pubTimestamp":1746522548,"startTime":"0","endTime":"0","summary":"截至2025年4月30日收市，于A股回购方案下，公司已累计回购731.06万股A股，累计回购金额约为人民币1.75亿元，最高价人民币25.39元/股、最低价人民币23.34元/股。2025年4月当月，公司回购共计70.95万股H股，回购总金额合计约为港币996.98万元，最高价港币14.30元/股、最低价港币13.94元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050617111097507a44&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050617111097507a44&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1593","02196","BK1515"],"gpt_icon":0},{"id":"2533293525","title":"癌症治疗新突破，复星医药新药拟纳入突破性治疗、再生元BCMAxCD3欧盟获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2533293525","media":"医药经济报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533293525?lang=zh_cn&edition=full","pubTime":"2025-05-06 13:38","pubTimestamp":1746509934,"startTime":"0","endTime":"0","summary":"公开资料显示，这是复星医药研发的创新型小分子化学药物芦沃美替尼。欧盟的批准是基于关键临床LINKER-MM1试验结果。这项试验纳入了117名接受200mg剂量 Lynozyfic 的复发/难治性多发性骨髓瘤患者结果显示，总缓解率ORR达到了71%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506145329a6d4a390&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506145329a6d4a390&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0096","BK0196","BK0239","BK0175","BK0183","BK0060","BK0187","BK0012","BK0188","600196","02196","BK0028"],"gpt_icon":0},{"id":"2533132200","title":"复星医药斥资近千万港元回购72.65万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2533132200","media":"DoNews","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533132200?lang=zh_cn&edition=full","pubTime":"2025-05-05 08:35","pubTimestamp":1746405302,"startTime":"0","endTime":"0","summary":"2025年5月2日，复星医药（02196）发布公告，以997.58万港元回购72.65万股。此次回购每股价格区间为13.56至13.82港元，彰显公司对自身发展的信心及维护股东权益的决心。免责声明：本文内容由开放的智能模型自动生成，仅供参考。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050508371694ec816a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050508371694ec816a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1515","BK1191","BK1593"],"gpt_icon":0},{"id":"2532281315","title":"复星医药(02196)5月2日斥资997.58万港元回购72.65万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2532281315","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532281315?lang=zh_cn&edition=full","pubTime":"2025-05-02 17:25","pubTimestamp":1746177905,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，于2025年5月2日斥资997.58万港元回购股份72.65万股，每股回购价格为13.56-13.82港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1289012.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02196","BK0196","BK0187","BK0012","BK0183","BK0188","BK0239","BK1191","BK0028","BK0096","BK1593","600196","BK0175","BK0060","BK1515"],"gpt_icon":0},{"id":"2532669891","title":"里昂：降复星医药目标价至15.6港元 维持“跑赢大市”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2532669891","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532669891?lang=zh_cn&edition=full","pubTime":"2025-05-02 15:46","pubTimestamp":1746171960,"startTime":"0","endTime":"0","summary":"该行认为，虽然盈利尚未出现明确的转势迹象，但预期近期的政策利好将为复苏铺路。里昂发布研报称，复星医药(02196) 2024年第四季和2025年第一季度业绩面临显著压力，主要原因是医药板块疲软。该行认为，虽然盈利尚未出现明确的转势迹象，但预期近期的政策利好将为复苏铺路。该行调低复星医药2025和2026年收入预测各11.6%及15.1%，下调纯利预测各8.9%及16%，并将H股目标价由15.8港元调低至15.6港元，维持“跑赢大市”评级。追加内容本文作者可以追加内容哦 !","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050215491194ea8e8f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050215491194ea8e8f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196"],"gpt_icon":0},{"id":"2532267896","title":"里昂：降复星医药(02196)目标价至15.6港元 维持“跑赢大市”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2532267896","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532267896?lang=zh_cn&edition=full","pubTime":"2025-05-02 15:27","pubTimestamp":1746170821,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，复星医药(02196) 2024年第四季和2025年第一季度业绩面临显著压力，主要原因是医药板块疲软。该行认为，虽然盈利尚未出现明确的转势迹象，但预期近期的政策利好将为复苏铺路。该行调低复星医药2025和2026年收入预测各11.6%及15.1%，下调纯利预测各8.9%及16%，并将H股目标价由15.8港元调低至15.6港元，维持“跑赢大市”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02196","600196"],"gpt_icon":0},{"id":"2532097627","title":"复星医药（600196）2025年一季报简析：净利润增25.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532097627","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532097627?lang=zh_cn&edition=full","pubTime":"2025-05-01 06:06","pubTimestamp":1746050786,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期复星医药发布2025年一季报。根据财报显示，复星医药净利润增25.42%。截至本报告期末，公司营业总收入94.2亿元，同比下降7.26%，归母净利润7.65亿元，同比上升25.42%。持有复星医药最多的基金为招商国证生物医药指数C，目前规模为18.39亿元，最新净值0.3528，较上一交易日下跌0.4%，近一年下跌10.89%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050100002964.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600196","02196"],"gpt_icon":0},{"id":"2532061311","title":"每周股票复盘：复星医药（600196）一季度归母净利润上升25.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532061311","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532061311?lang=zh_cn&edition=full","pubTime":"2025-05-01 01:54","pubTimestamp":1746035649,"startTime":"0","endTime":"0","summary":"截至2025年4月25日收盘，复星医药报收于24.14元，较上周的23.88元上涨1.09%。本周，复星医药4月22日盘中最高价报24.54元。本周关注点业绩披露要点：复星医药2025年一季报显示归母净利润7.65亿元，同比上升25.42%业绩披露要点复星医药2025年一季报显示，公司主营收入94.2亿元，同比下降7.26%；归母净利润7.65亿元，同比上升25.42%；扣非净利润4.1亿元，同比下降32.56%；负债率48.43%，投资收益12.81亿元，财务费用2.77亿元，毛利率47.77%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050100000635.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02196","600196"],"gpt_icon":0},{"id":"2531039761","title":"复星高科2025年一季度营收215.53亿 同比下降32.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531039761","media":"观点网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531039761?lang=zh_cn&edition=full","pubTime":"2025-04-30 19:30","pubTimestamp":1746012600,"startTime":"0","endTime":"0","summary":"观点网讯：4月30日，复星国际有限公司（以下简称“复星国际”）发布了复星高科技（集团）有限公司（复星高科）2025年第一季度报告。报告显示，复星高科总资产由上年度末的4030.45亿元减少至4045.67亿元，降幅为0.4%；归属于母公司股东之权益从921.57亿元增至918.93亿元，增长0.3%。营业总收入方面，复星高科2025年第一季度实现215.53亿元，较上年同期的321.11亿元下降32.9%；归属于母公司股东之利润为2762.6万元，相比上年同期的3799.6万元减少27.3%。免责声明：本文内容与数据由观点根据公开信息整理，不构成投资建议，使用前请核实。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043020074394e8eff0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043020074394e8eff0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","00656"],"gpt_icon":0},{"id":"2531036542","title":"复星医药新董事长“接棒”！公司一季度成绩单“出炉”","url":"https://stock-news.laohu8.com/highlight/detail?id=2531036542","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531036542?lang=zh_cn&edition=full","pubTime":"2025-04-30 19:19","pubTimestamp":1746011940,"startTime":"0","endTime":"0","summary":"4月29日盘后，复星医药发布2025年第一季度报告和新的董事会分工情况。今年第一季度复星医药营收94.2亿元，同比下滑7.26%；归母净利润7.65亿元，同比增长25.42%。2020年10月，吴以芳经选举担任复星医药第八届董事会董事长，至今已四年有余。一季度成绩单“出炉”业绩层面，复星医药2025年一季报已经披露。研发成果上，今年第一季度复星医药自主研发及许可引进的2个创新药分别在中国和欧盟获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043019270794e8e698&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043019270794e8e698&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02196","BK1593","600196","BK1515"],"gpt_icon":0},{"id":"2531038740","title":"复星医药董事长换帅","url":"https://stock-news.laohu8.com/highlight/detail?id=2531038740","media":"赛柏蓝器械","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531038740?lang=zh_cn&edition=full","pubTime":"2025-04-30 18:09","pubTimestamp":1746007740,"startTime":"0","endTime":"0","summary":"公告显示，一季度复星医药实现营业收入94.20亿元，同比下降7.26%；归母净利润7.65亿元，同比增长25.42%；经营活动现金流10.56亿元。今年3月，复星医药与和睦家在合作长达16年后正式“分手”。2024年复星医药医疗器械与医学诊断业务收入43.23亿，占营业收入比重10.53%。健嘉医疗由复星医药集团及国药控股共同出资设立。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-04-30/doc-ineuxwex0331969.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0183","BK0060","02196","BK0096","BK0196","BK0239","BK0175","BK1191","BK0028","BK1515","BK1593","BK0188","600196","BK0187","BK0012"],"gpt_icon":0},{"id":"2531085457","title":"复星医药(02196)4月30日耗资996.983万港元回购70.95万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2531085457","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531085457?lang=zh_cn&edition=full","pubTime":"2025-04-30 17:40","pubTimestamp":1746006043,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)公布，2025年4月30日耗资996.983万港元回购70.95万股股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288432.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","BK0175","600196","BK0060","BK0028","BK0196","BK1191","BK0096","BK0188","02196","BK1515","BK0183","BK0239","BK1593","BK0012"],"gpt_icon":0},{"id":"2531868810","title":"复星医药今年一季度归母净利润增长25.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531868810","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531868810?lang=zh_cn&edition=full","pubTime":"2025-04-30 16:54","pubTimestamp":1746003248,"startTime":"0","endTime":"0","summary":"4月29日，复星医药公布2025年第一季度业绩报告。报告期内，复星医药实现营业收入94.20亿元，同比下滑7.26%；归母净利润7.65亿元，同比增长25.42%；经营活动现金流10.56亿元。营收下滑主要是受药品集采续标及部分地方药品集采开展的影响。报告期内，复星医药持续推进非战略非核心资产的退出和整合，持续推进资产结构优化，加速现金回流。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504303394542974.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504303394542974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02196"],"gpt_icon":0},{"id":"2531003107","title":"复星医药04月30日主力净流出979.1万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2531003107","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531003107?lang=zh_cn&edition=full","pubTime":"2025-04-30 16:15","pubTimestamp":1746000906,"startTime":"0","endTime":"0","summary":"04月30日, 复星医药股价跌3.72%，报收13.98元，成交金额1.3亿元，换手率1.65%，振幅3.31%，量比2.23。复星医药今日主力资金净流出979.1万元，上一交易日主力净流入309.8万元。该股近5个交易日下跌4.92%，主力资金累计净流出592.3万元；近20日主力资金累计净流入198.8万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170143a6ce97c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170143a6ce97c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","02196","BK1191","BK1515"],"gpt_icon":0},{"id":"2531704494","title":"医药上市企业Q1数据分析，化药复星第1、中药白云山第1，总营收2650亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2531704494","media":"风云药谈","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531704494?lang=zh_cn&edition=full","pubTime":"2025-04-30 13:03","pubTimestamp":1745989419,"startTime":"0","endTime":"0","summary":"医药行业上市企业Q1的季度报基本上已经出完，总统计320家，总营收2650亿，净利330亿，销售费用479亿，研发费用169亿。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430163729a6ce8e6f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430163729a6ce8e6f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159938","02196","600196","600332","00874","562390","00656","561510"],"gpt_icon":0},{"id":"2531376007","title":"图解复星医药一季报：第一季度单季净利润同比增25.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531376007","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531376007?lang=zh_cn&edition=full","pubTime":"2025-04-30 02:42","pubTimestamp":1745952166,"startTime":"0","endTime":"0","summary":"证券之星消息，复星医药2025年一季报显示，公司主营收入94.2亿元，同比下降7.26%；归母净利润7.65亿元，同比上升25.42%；扣非净利润4.1亿元，同比下降32.56%；负债率48.43%，投资收益12.81亿元，财务费用2.77亿元，毛利率47.77%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025043000001657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600196","02196"],"gpt_icon":0},{"id":"2531764123","title":"复星医药(600196.SH)发布一季度业绩，归母净利润7.65亿元，同比增长25.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531764123","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531764123?lang=zh_cn&edition=full","pubTime":"2025-04-30 01:33","pubTimestamp":1745948031,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布2025年第一季度报告，公司一季度营业收入94.20亿元;归属于上市公司股东的净利润7.65亿元，同比增长25.42%;归属于上市公司股东的扣除非经常性损益的净利润4.10亿元;基本每股收益0.29元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288064.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02196","600196"],"gpt_icon":0},{"id":"2531732054","title":"复星医药换帅：陈玉卿接棒吴以芳任董事长，吴以芳改任复星国际执行总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2531732054","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531732054?lang=zh_cn&edition=full","pubTime":"2025-04-29 21:05","pubTimestamp":1745931918,"startTime":"0","endTime":"0","summary":"在公布一季报之际，履职不到5年的吴以芳辞任复星医药董事长一职，现任复星国际高级副总裁接任董事长一职。4月29日晚间，复星医药（600196.SH；2196.HK）发布公告称，近日，董事会收到吴以芳、王可心的书面辞职函，因工作安排调整，吴以芳、王可心分别辞去公司董事长、联席董事长职务。根据公司章程规定，辞任自2025年4月29日生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504293393218813.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504293393218813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK1515","BK1593","00656","02196","BK1230"],"gpt_icon":0},{"id":"2531736684","title":"复星医药最新公告：一季度净利同比增长25.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531736684","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531736684?lang=zh_cn&edition=full","pubTime":"2025-04-29 20:40","pubTimestamp":1745930413,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，公司发布2025年第一季度报告，实现营业收入94.20亿元，同比下降7.26%；归属于上市公司股东的净利润为7.65亿元，同比增长25.42%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042900038886.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0188","BK0187","BK0183","BK0175","BK1593","BK0060","02196","BK1515","600196","BK0196","BK1191","BK0096","BK0012"],"gpt_icon":0},{"id":"2531736680","title":"复星医药最新公告：控股子公司复宏汉霖与SandozAG签署许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2531736680","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531736680?lang=zh_cn&edition=full","pubTime":"2025-04-29 20:39","pubTimestamp":1745930368,"startTime":"0","endTime":"0","summary":"复星医药公告称，公司控股子公司复宏汉霖与SandozAG签订《合作与许可协议》，复宏汉霖授予SandozAG于许可区域及领域开发、生产及商业化其在研产品HLX13的权利。SandozAG需支付至多19,100万美元的款项，包括首付款和开发里程碑款项。同时，SandozAG需按约定百分比向复宏汉霖支付利润分成款。该协议自签署之日起生效，有效期至许可产品于许可区域首次商业化销售之日起15年，可自动续期5年。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042900038885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0188","BK0196","BK0239","BK1593","BK0028","BK1161","BK0183","BK0096","BK0175","BK1191","600196","BK1515","02696","BK0187","02196","BK0012"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":-0.0399},{"period":"1month","weight":-0.1121},{"period":"3month","weight":0.045},{"period":"6month","weight":-0.1041},{"period":"1year","weight":0.1198},{"period":"ytd","weight":-0.0127}],"compareEarnings":[{"period":"1week","weight":0.0297},{"period":"1month","weight":-0.0082},{"period":"3month","weight":0.1003},{"period":"6month","weight":0.0816},{"period":"1year","weight":0.2198},{"period":"ytd","weight":0.1297}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司经营五个分部。制药分部主要从事创新药、成熟医药产品制造和疫苗业务。医疗器械与医学诊断分部主要从事分子诊断、免疫诊断、微生物诊断等医疗美容器械的制造和销售。医疗健康服务分部主要从事线上线下一体化医疗服务平台的经营。医药分销和零售分部主要从事医药产品的批发零售。其他分部从事其他医药相关业务。该公司的产品主要用于肿瘤、免疫、中枢神经等治疗领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.384615,"avgChangeRate":-0.051332},{"month":2,"riseRate":0.769231,"avgChangeRate":0.040452},{"month":3,"riseRate":0.615385,"avgChangeRate":0.048435},{"month":4,"riseRate":0.384615,"avgChangeRate":0.03075},{"month":5,"riseRate":0.384615,"avgChangeRate":0.021513},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.030979},{"month":7,"riseRate":0.583333,"avgChangeRate":0.016786},{"month":8,"riseRate":0.25,"avgChangeRate":-0.056338},{"month":9,"riseRate":0.416667,"avgChangeRate":-0.002922},{"month":10,"riseRate":0.5,"avgChangeRate":0.028405},{"month":11,"riseRate":0.461538,"avgChangeRate":0.046299},{"month":12,"riseRate":0.461538,"avgChangeRate":0.021542}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.3","shortVersion":"4.33.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}